drugset / Trial / NCT05181683
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab The secondary objectives of the study are to: * Explore variability in the drug concentration profiles of casirivimab and imdevimab after co-formulated subcutaneous (SC) or intravenous (IV) administration * Characterize the immunogenicity of casirivimab and imdevimab in serum over time
Timeline
- Start
- 2022-01-07
- Primary completion
- 2022-06-03
- Completion
- 2022-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | casirivimab | Monoclonal antibody | — | Intravenous |
| Subject | imdevimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.